J. Schmidt

Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens

B. Bittner, M. Philippart, J. Schmidt, 2015, Drug Research.

Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women

M. Castelli, B. Bittner, C. McIntyre, 2011 .

Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab

F. Hourcade‐Potelleret, B. Bittner, W. Richter, 2014, Drug Research.

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

F. Hourcade‐Potelleret, B. Bittner, W. Richter, 2012, Arzneimittelforschung/Drug Research.

Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).

N. Fotaki, N. Shah, H. Chokshi, 2012, Die Pharmazie.

賦形剤N-[8-(2-ヒドロキシベンゾイル)アミノ]カプリル酸ナトリウム含有イバンドロナートについて新規経口製剤選択のための第I相臨床試験

N. Fotaki, N. Shah, H. Chokshi, 2012 .

Subcutaneous drug delivery devices—Enablers of a flexible care setting

B. Bittner, J. Schmidt, 2021 .